Inhibition of TLR activation and up-regulation of IL-IR-associated kinase-M expression by exogenous gangliosides

Journal of Immunology

Volumn 180, Issue 7, 2008, Pages 4425-4432

  Shen, Weiping ^a,b   Stone, Kelly ^a,b   Jales, Alessandra ^a   Leitenberg, David ^a   Ladisch, Stephan ^a,b,c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b CHILDREN S RESEARCH INSTITUTE   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GM1; GANGLIOSIDE GM3; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE M; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG; CYTOKINE; GANGLIOSIDE; GANGLIOSIDE, GD1A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRAK3 PROTEIN, HUMAN; LIGAND; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR;

ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; INNATE IMMUNITY; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; CELL CULTURE; CELL NUCLEUS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LEUKOCYTE; METABOLISM; SECRETION;

CELL MEMBRANE; CELL NUCLEUS; CELLS, CULTURED; CYTOKINES; GANGLIOSIDES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LEUKOCYTES; LIGANDS; LIPOPOLYSACCHARIDES; NF-KAPPA B; TOLL-LIKE RECEPTORS; UP-REGULATION;

EID: 44449154904     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.7.4425     Document Type: Article

References (59)

1. Ladisch, S., B. Gillard, C. Wong, and L. Ulsh. 1983. Shedding and immuno- regulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res. 43: 3808-3813.
2. Chang, F., R. Li, and S. Ladisch. 1997. Shedding of gangliosides by human medulloblastoma cells. Exp. Cell Res. 234: 341-346.
3. Bernhard, H., K. H. Meyer zum Buschenfelde, and W. G. Dippold. 1989. Ganglioside GD3 shedding by human malignant melanoma cells. Int. J. Cancer 44: 155-160.
4. Portoukalian, J., M. J. David, P. Gain, and M. Richard. 1993. Shedding of GD2 ganglioside in patients with retinoblastoma. Int. J. Cancer 53: 948-951.
5. Ladisch, S., and Z. L. Wu. 1985. Detection of a tumour-associated ganglioside in plasma of patients with neuroblastoma. Lancet 1: 136-138.
6. Valentino, L., T. Moss, E. Olson, H. J. Wang, R. Elashoff, and S. Ladisch. 1990. Shed tumor gangliosides and progression of human neuroblastoma. Blood 75: 1564 -1567.
7. Ikeda, T., H. Nakakuma, H. Shionoya, T. Kawaguchi, K. Yamatsu, and K. Takatsuki. 1992. Ganglioside-induced inhibition of in vivo immune response in mice. Life Sci. 51: 847-851.
8. Ladisch, S., S. Kitada, and E. F. Hays. 1987. Gangliosides shed by tumor cells enhance tumor formation in mice. J. Clin. Invest. 79: 1879-1882.
9. McKallip, R., R. Li, and S. Ladisch. 1999. Tumor gangliosides inhibit the tumor- specific immune response. J. Immunol. 163: 3718-3726.
10. Uzzo, R. G., P. Rayman, V. Kolenko, P. E. Clark, M. K. Cathcart, T. Bloom, A. C. Novick, R. M. Bukowski, T. Hamilton, and J. H. Finke. 1999. Renal cell carcinoma-derived gangliosides suppress nuclear factor-KB activation in T cells. J. Clin. Invest. 104: 769 -776.
11. Simons, K., and D. Toomre. 2000. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1: 31-39.
12. Heitger, A., and S. Ladisch. 1996. Gangliosides block antigen presentation by human monocytes. Biochim. Biophys. Acta 1303: 161-168.
13. Ladisch, S., L. Ulsh, B. Gillard, and C. Wong. 1984. Modulation of the immune response by gangliosides: inhibition of adherent monocyte accessory function in vitro. J. Clin. Invest. 74: 2074-2081.
14. Miller, H. C., and W. J. Esselman. 1975. Modulation of the immune response by antigen-reactive lymphocytes after cultivation with gangliosides. J. Immunol. 115: 839 -843.
15. Whisler, R. L., and A. J. Yates. 1980. Regulation of lymphocyte responses by human gangliosides. I. Characteristics of inhibitory effects and the induction of impaired activation. J. Immunol. 125: 2106 -2111.
16. Ladisch, S., H. Becker, and L. Ulsh. 1992. Immunosuppression by human gan- gliosides. I. Relationship of carbohydrate structure to the inhibition of T cell responses. Biochim. Biophys. Acta 1125: 180 -188.
17. Shen, W., R. Falahati, R. Stark, D. Leitenberg, and S. Ladisch. 2005. Modulation of CD4 Th cell differentiation by ganglioside GD1a in vitro. J. Immunol. 175: 4927-4934.
18. Jensen, C., U. G. Svendsen, O. Thastrup, P. Stahl Skov, A. Leon, and S. Norn. 1987. Complexity of the influence of gangliosides on histamine release from human basophils and rat mast cells. Agents Actions 21: 79 -82.
19. Shen, W., and S. Ladisch. 2002. Ganglioside GD1a impedes lipopolysaccharide- induced maturation of human dendritic cells. Cell Immunol. 220: 125-133.
20. Caldwell, S., A. Heitger, W. Shen, Y. Liu, B. Taylor, and S. Ladisch. 2003. Mechanisms of ganglioside inhibition of APC function. J. Immunol. 171: 1676 -1683.
21. + hematopoietic progenitors. Eur. Urol. 39 (Suppl. 4): 37-40.
22. Cavaillon, J. M., C. Fitting, B. Hauttecoeur, and N. Haeffner-Cavaillon. 1987. Inhibition by gangliosides of the specific binding of lipopolysaccharide (LPS) to human monocytes prevents LPS-induced interleukin-1 production. Cell Immunol. 106: 293-303.
23. West, A. P., B. A. Dancho, and S. B. Mizel. 2005. Gangliosides inhibit flagellin signaling in the absence of an effect on flagellin binding to toll-like receptor 5. J. Biol. Chem. 280: 9482-9488.
24. Medzhitov, R., P. Preston-Hurlburt, and C. A. Janeway, Jr. 1997. A human ho- mologue of the Drosophila toll protein signals activation of adaptive immunity. Nature 388: 394-397.
25. Yang, R. B., M. R. Mark, A. Gray, A. Huang, M. H. Xie, M. Zhang, A. Goddard, W. I. Wood, A. L. Gurney, and P. J. Godowski. 1998. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 395: 284-288.
26. Schroder, N. W., S. Morath, C. Alexander, L. Hamann, T. Hartung, U. Zahringer, U. B. Gobel, J. R. Weber, and R. R. Schumann. 2003. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via toll-like receptor (TLR)-2, lipopolysaccharide- binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J. Biol. Chem. 278: 15587-15594.
27. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-κB by toll-like receptor 3. Nature 413: 732-738.
28. Lund, J. M., L. Alexopoulou, A. Sato, M. Karow, N. C. Adams, N. W. Gale, A. Iwasaki, and R. A. Flavell. 2004. Recognition of single-stranded RNA viruses by toll-like receptor 7. Proc. Natl. Acad. Sci. USA 101: 5598-5603.
29. Triantafilou, M., K. Miyake, D. T. Golenbock, and K. Triantafilou. 2002. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J. Cell Sci. 115: 2603-2611.
30. Akira, S. 2003. Toll-like receptor signaling. J. Biol. Chem. 278: 38105-38108.
31. Beutler, B. 2004. Inferences, questions and possibilities in toll-like receptor signalling. Nature 430: 257-263.
32. Michelsen, K. S., A. Aicher, M. Mohaupt, T. Hartung, S. Dimmeler, C. J. Kirschning, and R. R. Schumann. 2001. The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS): pepti- doglycan and lipoteichoic acid are inducers of DC maturation and require TLR2. J. Biol. Chem. 276: 25680 -25686.
33. Hertz, C. J., and R. L. Modlin. 2003. Role of toll-like receptors in response to bacterial infection. Contrib. Microbiol. 10: 149 -163.
34. Wald, D., J. Qin, Z. Zhao, Y. Qian, M. Naramura, L. Tian, J. Towne, J. E. Sims, G. R. Stark, and X. Li. 2003. SIGIRR, a negative regulator of toll-like receptor- interleukin 1 receptor signaling. Nat. Immunol. 4: 920 -927.
35. Brint, E. K., D. Xu, H. Liu, A. Dunne, A. N. McKenzie, L. A. O'Neill, and F. Y. Liew. 2004. ST2 is an inhibitor of interleukin 1 receptor and toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol 5: 373-379.
36. Garlanda, C., F. Riva, N. Polentarutti, C. Buracchi, M. Sironi, M. De Bortoli, M. Muzio, R. Bergottini, E. Scanziani, A. Vecchi, et al. 2004. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc. Natl. Acad. Sci. USA 101: 3522-3526.
37. Kobayashi, K., L. D. Hernandez, J. E. Galan, C. A. Janeway, Jr., R. Medzhitov, and R. A. Flavell. 2002. IRAK-M is a negative regulator of toll-like receptor signaling. Cell 110: 191-202.
38. Kinjyo, I., T. Hanada, K. Inagaki-Ohara, H. Mori, D. Aki, M. Ohishi, H. Yoshida, M. Kubo, and A. Yoshimura. 2002. SOCS1/JAB is a negative regulator of LPS- induced macrophage activation. Immunity 17: 583-591.
39. Chuang, T. H., and R. J. Ulevitch. 2004. Triad3A, an E3 ubiquitin-protein ligase regulating toll-like receptors. Nat. Immunol. 5: 495-502.
40. Hornung, V., S. Rothenfusser, S. Britsch, A. Krug, B. Jahrsdorfer, T. Giese, S. Endres, and G. Hartmann. 2002. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168: 4531-4537.
41. Kadowaki, N., S. Antonenko, S. Ho, M. C. Rissoan, V. Soumelis, S. A. Porcelli, L. L. Lanier, and Y. J. Liu. 2001. Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells. J. Exp. Med. 193: 1221-1226.
42. Nakayama, K., S. Okugawa, S. Yanagimoto, T. Kitazawa, K. Tsukada, M. Kawada, S. Kimura, K. Hirai, Y. Takagaki, and Y. Ota. 2004. Involvement of IRAK-M in peptidoglycan-induced tolerance in macrophages. J. Biol. Chem. 279: 6629 -6634.
43. Del Fresno, C., K. Otero, L. Gomez-Garcia, M. C. Gonzalez-Leon, L. Soler-Ranger, P. Fuentes-Prior, P. Escoll, R. Baos, L. Caveda, F. Garcia, et al. 2005. Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J. Immunol. 174: 3032-3040.
44. Zitvogel, L., A. Tesniere, and G. Kroemer. 2006. Cancer despite immunosur- veillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6: 715-727.
45. Rosenberg, S. A., and M. E. Dudley. 2004. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. USA 101 (Suppl. 2): 14639 -14645.
46. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126 -129.
47. Olshefski, R., and S. Ladisch. 1996. Intercellular transfer of shed tumor cell gangliosides. FEBS Lett. 386: 11-14.
48. Jury, E. C., P. S. Kabouridis, F. Flores-Borja, R. A. Mageed, and D. A. Isenberg. 2004. Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J. Clin. Invest. 113: 1176 -1187.
49. Krishnan, S., M. P. Nambiar, V. G. Warke, C. U. Fisher, J. Mitchell, N. Delaney, and G. C. Tsokos. 2004. Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J. Immunol. 172: 7821-7831.
50. Peguet-Navarro, J., M. Sportouch, I. Popa, O. Berthier, D. Schmitt, and J. Portoukalian. 2003. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J. Immunol. 170: 3488 -3494.
51. Wolfl, M., W. Y. Batten, C. Posovszky, H. Bernhard, and F. Berthold. 2002. Gangliosides inhibit the development from monocytes to dendritic cells. Clin. Exp. Immunol. 130: 441-448.
52. Bronnum, H., T. Seested, L. I. Hellgren, S. Brix, and H. Frokiaer. 2005. Milk- derived GM(3) and GD(3) differentially inhibit dendritic cell maturation and effector functionalities. Scand. J. Immunol. 61: 551-557.
53. Gomez-Mouton, C., J. L. Abad, E. Mira, R. A. Lacalle, E. Gallardo, S. Jimenez-Baranda, I. Illa, A. Bernad, S. Manes, and A. C. Martinez. 2001. Segregation of leading-edge and uropod components into specific lipid rafts during T cell polarization. Proc. Natl. Acad. Sci. USA 98: 9642-9647.
54. Miljan, E. A., and E. G. Bremer. 2002. Regulation of growth factor receptors by gangliosides. Sci. STKE 2002: RE15.
55. Liu, Y., R. Li, and S. Ladisch. 2004. Exogenous ganglioside GD1a enhances epidermal growth factor receptor binding and dimerization. J. Biol. Chem. 279: 36481-36489.
56. Cavaillon, J. M., and M. Adib-Conquy. 2006. Bench-to-bedside review: endo- toxin tolerance as a model of leukocyte reprogramming in sepsis. Crit. Care 10: 233.
57. Escoll, P., C. del Fresno, L. Garcia, G. Valles, M. J. Lendinez, F. Arnalich, and E. Lopez-Collazo. 2003. Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients. Biochem. Biophys. Res. Commun. 311: 465-472.
58. Mond, J. J., K. Witherspoon, R. K. Yu, P. Y. Perera, and S. N. Vogel. 1994. Inhibition of LPS-mediated cell activation in vitro and in vivo by gangliosides. Circ. Shock. 44: 57-62.
59. Jiang, D., J. Liang, J. Fan, S. Yu, S. Chen, Y. Luo, G. D. Prestwich, M. M. Mascarenhas, H. G. Garg, D. A. Quinn, et al. 2005. Regulation of lung injury and repair by toll-like receptors and hyaluronan. Nat. Med. 11: 1173-1179.